Pricing Log in Create free account

Aktis Oncology, Inc. (AKTS) vs Savara Inc. (SVRA)

Aktis Oncology, Inc. and Savara Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Savara Inc. are of similar size ($973.9M and $890.5M). Savara Inc. has the higher net margin (0.00% vs −782.0%) and the lower return on invested capital (−12,213.2% vs 0.00%). Across the 14 metrics below, Aktis Oncology, Inc. leads on 7 and Savara Inc. on 7.

Valuation

Metric AKTS SVRA Biotechnology median
P/E n/m n/m 8.50
P/S 86.22 n/m 9.71
P/B 1.72 7.85 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 32.66 n/m 9.21
Earnings yield (277.60%) (13.03%) (33.15%)
Free cash flow yield (16.73%) (9.81%) (25.50%)

Profitability

Metric AKTS SVRA Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (939.13%) 0.00% 0.00%
Net margin (781.95%) 0.00% 0.00%
Free cash flow margin (1,442.91%) 0.00% 0.00%
Return on equity (34.45%) (105.48%) (56.36%)
Return on assets (22.22%) (78.28%) (48.04%)
Return on invested capital 0.00% (12,213.18%) 0.00%

Growth

Metric AKTS SVRA Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (25.43%) (10.42%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AKTS SVRA Biotechnology median
Debt to equity 0.00 0.21 0.00
Current ratio 16.33 10.13 4.72
Net debt to EBITDA 2.95 1.64 0.96

Dividend

Metric AKTS SVRA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AKTS SVRA Biotechnology median
Market cap 890.47m 973.88m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack